Scientific Sessions
  • #AHA22
  • Virtual Experience Access
  • Sessions Posters
  • Late-Breaking Science
  • Daily Coverage
  • Industry Highlights
  • Featured Exhibitors
  • Program
  • Previews
Topics
  • Late-Breaking Science
  • Daily Coverage
  • Industry Highlights
  • Featured Exhibitors
  • Program
  • Previews
Resources
  • #AHA22
  • Virtual Experience Access
  • Sessions Posters
User Tools
  • Privacy Policy
  • Terms & Conditions
  • Accessibility Statement
Twitter iconFacebook iconInstagram iconYouTube iconPinterest iconLinkedIn icon
Nov 14th, 2020

Ablation, lifestyle changes may be better ways to manage atrial fibrillation, presenters say


Getty Images 473291878

It’s time to shift clinical management of atrial fibrillation to ablation and lifestyle changes, suggest presenters in Saturday’s “Atrial Fibrillation: Time for a Paradigm Shift in Management” session.

Revised AF guidelines recommend ablation as an alternative to medication and recent studies reveal it may become first-line treatment for some patients.

Meanwhile, early clinical work shows strong potential for lifestyle management to treat and possibly reverse structural damage caused by AF.

AFFIRM and other randomized studies consistently show similar survival benefits from rate and rhythm control strategies for AF in intention-to-treat analyses, said Andrea M. Russo, MD, professor of medicine and director of electrophysiology and arrhythmia services at Cooper Medical School of Rowan University in Camden, New Jersey.

But more recent results suggest that rhythm control plus ablation may be beneficial in some situations. Recent data also indicate that early ablation is preferred because it limits the atrial wall restructuring that can develop over time to worsen clinical outcomes in some patients.

The presence of heart failure complicates AF treatment, said Jennifer Wright, MD, associate professor of medicine at the University of Wisconsin School of Medicine and Public Health in Madison. Patients with HF and reduced ejection fraction (HFrEF) have no mortality benefit from rhythm-control medications. Catheter ablation reduces mortality and hospitalization for HFrEF patients with AF.

Ablation also appears to maintain ejection fraction in patients with HF and preserved ejection fraction (HFpEF), although more data are needed, Dr. Wright said.

“Catheter ablation is a game changer for management of our heart failure patients with AF,” she said.

Patients more likely to benefit from ablation include those with suspected AF-induced or mediated cardiomyopathy, NYHA Class I/II, no significant ventricular scar, paroxysmal or early persistent AF and those with no significant comorbidities, said Rakesh Gopinathannair, MD, professor of medicine at the University of Missouri and director of the Cardiac Electrophysiology Lab at the Kansas City Heart Rhythm Institute.

Patients with advanced HF and/or severe left ventricle dysfunction, significant ventricular scarring on MRI, severe atrial myopathy, longstanding persistent AF, prior failed ablation and advanced age or significant comorbidities are less favorable for ablation.

Randomized trials in HFrEF patients found about a 50% hazard ratio for mortality at five years following ablation compared to medication, Dr. Gopinathannair said. HFrEF likely induces or mediates occult AF cardiomyopathy that requires rhythm control, and ablation has better short- and long-term success than anti-arrhythmic medications. Ablation also avoids the adverse effects associated with long-term anti-arrhythmic medication, he said.

“Reducing the AF burden is the secret  ingredient of ablation leading to improvement,” Dr. Gopinathannair said. “Even if catheter ablation cannot cure AF, it can significantly reduce the burden. And that’s what you need for good long-term outcomes. It is time for a shift in the paradigm. In eligible patients with AF and HFrEF, catheter ablation should be first-line therapy.”

Moving from medication to ablation may not be the final paradigm shift in AF, Gopinathannair said. Modifiable risk factors, including alcohol intake, diabetes, hypertension, obesity, physical inactivity, sleep apnea, dyslipidemia and smoking, lead to mechanistic changes that favor AF despite ablation or other treatment.

Prashanthan Sanders, MD, director of the Center for Heart Rhythm Disorders at the University of Adelaide in Australia, suggests altering the phenotype of AF through lifestyle management strategies to reduce the burden of AF and reverse disease progression.

 

Interesting Stories
New Double Take Videos from NEJM
Sponsored by NEJM Group
New Double Take Videos from NEJM
MiCare Path joins the AHA CHTI and will integrate AHA science-based
Sponsored by MiCare Path
MiCare Path joins the AHA CHTI and will integrate AHA science-based
Modern Wearable Defibrillation
Sponsored by Kestra Medical Technologies
Modern Wearable Defibrillation
Data-driven precision medicine
Sponsored by Tempus
Data-driven precision medicine
More Content
Manesh Patel
AHA22
#AHA 22 Closing Session: That’s a wrap
Nov 9th, 2022
Getty Images 1388100332
AHA22
Congratulations to the winners of the Wellness Challenge and Scavenger Hunt
Nov 8th, 2022
puppy snugglers
AHA22
Special Recognition to the Hinsdale Humane Society
Nov 8th, 2022
audience shot
AHA22
Trial results shed light on tool for assessing VTE risk, routine anticoagulation for non-hospitalized COVID patients, and clinical outcomes of open vs. endovascular surgery for advanced PAD
Nov 8th, 2022
audience shot
AHA22
Bivalirudin superior to unfractionated heparin in primary PCI following STEMI
Nov 8th, 2022
Panelists of the Mindful Disruption panel
Late-Breaking Science
Overcoming health disparities, health care advocates and mindfulness can better manage BP and CVD
Nov 7th, 2022
Medtech
AHA22
Medtech is getting smarter — and so is patient care
Nov 7th, 2022
med tech checking fluids in a hospital
AHA22
New digital hub offers professional education to complement lifelong learning
Nov 7th, 2022
Aha22 Sm 2334
AHA22
Trial results report on benefits of radial artery for CABG, use of prophylactic methylprednisolone and ECMO for patients in cardiogenic shock
Nov 7th, 2022
runner montage
AHA22
And the Health Tech Competition winner is…
Nov 7th, 2022
Aha Ss22 Days123 Pg1
AHA22
Read all about it
Nov 7th, 2022
Screen Shot 2022 11 06 At 10 45 03 Am
AHA22
Science, medicine must be a ‘relentless force’ in fighting misinformation
Nov 6th, 2022